Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Assets (2020 - 2025)

Oncology Institute's Assets history spans 6 years, with the latest figure at $164.7 million for Q4 2025.

  • For Q4 2025, Assets fell 4.67% year-over-year to $164.7 million; the TTM value through Dec 2025 reached $164.7 million, down 4.67%, while the annual FY2025 figure was $164.7 million, 4.67% down from the prior year.
  • Assets reached $164.7 million in Q4 2025 per TOI's latest filing, up from $163.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $283.8 million in Q3 2022 to a low of $159.8 million in Q2 2025.
  • Average Assets over 5 years is $205.9 million, with a median of $205.5 million recorded in 2022.
  • Peak YoY movement for Assets: soared 209.7% in 2021, then dropped 23.06% in 2023.
  • A 5-year view of Assets shows it stood at $203.4 million in 2021, then grew by 28.62% to $261.7 million in 2022, then dropped by 20.04% to $209.2 million in 2023, then decreased by 17.46% to $172.7 million in 2024, then fell by 4.67% to $164.7 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Assets are $164.7 million (Q4 2025), $163.6 million (Q3 2025), and $159.8 million (Q2 2025).